{"id":"expectation-framing-hearts","title":"Frame side-effect warnings so patients keep taking their blood-pressure drugs","status":"proposed combination, not yet tested as a combination","headline":"A one-page script changes how nurses and pharmacists describe common side effects (most are mild, and most feelings of \"side effects\" occur equally on a dummy pill), to cut the share of patients who stop treatment.","domain":"Health","problem":"Heart disease and stroke: people stop their blood-pressure pills because of side effects they were told to expect","transfer":{"from":"statin trials in high-income countries that measured the nocebo effect","to":"primary-care hypertension programmes in low- and middle-income countries"},"mechanism":"Blinded n-of-1 and trial-extension studies of statins found that most symptoms people report on treatment also appear on a dummy pill, and that unblinded patients report more. Telling people what to expect shapes what they feel (the nocebo effect). Stopping treatment because of feared side effects is a major reason blood pressure stays uncontrolled; a framing script costs almost nothing to add to a protocol that already exists.","components":["hypertension"],"evidence":[{"role":"size of the nocebo effect","cite":"Wood et al., New England Journal of Medicine, 2020","supports":"In a blinded n-of-1 trial, symptom intensity was nearly the same on statin and on placebo and much lower in months with no tablet: almost the whole increase appeared on the dummy pill too (figures are in the paper body, not its abstract).","doi":"10.1056/nejmc2031173","verified":true},{"role":"unblinded patients report more","cite":"Gupta et al., The Lancet, 2017","supports":"Muscle symptoms were reported 41% more often on statin when patients knew they were taking it, and not more often when blinded.","doi":"10.1016/s0140-6736(17)31075-9","verified":true},{"role":"the mechanism, reviewed","cite":"Colloca and Barsky, New England Journal of Medicine, 2020","supports":"Review of how expectations and the wording of warnings shape side effects and treatment adherence.","doi":"10.26226/morressier.5cf632c0af72dec2b0554738","verified":true},{"role":"size of the adherence gap","cite":"Abegaz et al., Medicine, 2017","supports":"Systematic review of non-adherence to blood-pressure drugs worldwide.","doi":"10.1097/md.0000000000005641","verified":true}],"closest_prior_work":[],"benefit_cost":{"metric":"WELLBY per USD 1,000","per_1000_usd":{"n":3000,"mean":1.9433667045484413,"p5":0.09854148998351825,"p25":0.48463359756210644,"p50":1.049893336548995,"p75":2.333303003670353,"p95":6.576657324548838},"cost_per_daly":{"low":111,"high":2000,"note":"direct effect only; interval is the range of the assumption, not a statistical confidence interval"},"evidence_share":{"A":0,"B":0,"C":0,"D":1},"prob_net_positive":0.9776666666666667,"cost_assumption":"USD 5,000 for about 10,000 patients on treatment across 20 clinics: script design, one training session per clinic, printed cards (assumption)."},"first_test":"20 clinics in one district, randomised 10 and 10 within a protocol that already runs. Intervention clinics use the script at the first prescription and at each refill. Primary outcome: share of new patients still collecting drugs at 6 months, from refill records. Safety outcome: serious adverse events reported to the clinic, to confirm that honest framing does not hide real harm. Stop rule: the pilot fails if retention at 6 months is not at least 5 points higher, or if serious events are higher in intervention clinics.","who":"National hypertension programmes using WHO HEARTS, primary-care trainers, pharmacist associations.","takes":"A one-page counselling script, an hour of nurse training, a printed card for the patient, and a question at refill visits that records why anyone stopped.","risks":["The script could be read as dismissing a real reaction; the pilot has patients flag any symptom for a clinician anyway.","Counselling time is scarce; the script is meant to replace, not add to, the standard warning.","Refill records may not capture patients who switch to another pharmacy."],"limits":"The nocebo evidence is strongest for statins, not blood-pressure drugs, and for patients in rich countries. Framing might reduce honest reporting of a real adverse effect, which is why the pilot measures serious events. The size of the effect on retention is unknown until a trial runs.","verified_at":"2026-11-18T15:19:57.209Z","url":"https://tenant-ps-web.ultrastable.workers.dev/syntheses/expectation-framing-hearts"}